View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Eurofins Genomics
2 March 2014

Quantification of Residual DNA from Production Strains or Cell Lines in Biopharmaceutical and Biotechnological Products

Protein based diagnostics and therapeutics gain more and more importance. These molecules are produced utilising production strains and cell lines ranging from bacteria to mammalian cell lines.

Biologicals such as antibodies may be contaminated with traces of nucleic acids. This residualDNA or host cell DNA is derived from the production strains (e.g. bacterial strains) or cell lines and is usually co-purified during manufacturing and purification processes.

Regulatory authorities allow only very little amounts of remaining host cell DNA in biologicals.Particularly, if genetically modified organisms are used, the amount of the production strain has to be quantified during the production and purification steps as well as in the end product.

Highest accuracy and sensitivity can be achieved by quantitative Real-Time PCR targeting specific DNA targets of the production strain or cell line. The development and validation of such tests are key competencies at Eurofins Medigenomix in Ebersberg, Germany.

Residual DNA testing is performed in an ISO 17025 accredited laboratory and according to GxP standards. This service is also offered at Eurofins Lancaster Laboratories in the US.

Pharmacogenetic and pharmacogenomic analysis of the effects of pharmaceutical compounds helps to realise the concept of individualised drug therapy or personalised medicine.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology